ReviewPituitary2012
Medical management of Cushing's disease: what is the future?
Review in Pituitary, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.Pituitary · 2016Pooled it
- Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Pituitary · 2016Trial
- Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.The Journal of clinical endocrinology and metabolism · 2014Trial
- Global clinical response in Cushing's syndrome patients treated with mifepristone.Clinical endocrinology · 2014Trial
- Adrenocorticotropin-secreting pituitary macroadenomas: expanding the clinical spectrum.JCEM case reports · 2026Article
- Management of patients with Cushing's disease in the Gulf Region: a Delphi consensus recommendation.Frontiers in endocrinology · 2025Article
- The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.Cancers · 2023Review
- Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort.Frontiers in endocrinology · 2022Article
- A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.Frontiers in endocrinology · 2020Article
- The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".Endocrine · 2019Article
- Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement.Endocrinology and metabolism (Seoul, Korea) · 2019Review
- The role of Crooke's changes in recurrence and remission after gamma knife radiosurgery.Journal of neuro-oncology · 2019Article
- Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.The Journal of pharmacology and experimental therapeutics · 2018Article
- Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis.Frontiers in endocrinology · 2018Article
- New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.Frontiers in endocrinology · 2018Review
- Inhibitory Effects of a Novel PPAR-PPAR research · 2018Article
- Pituitary-Directed Therapies for Cushing's Disease.Frontiers in endocrinology · 2018Review
- Is there a role for early chemotherapy in the management of pituitary adenomas?Neuro-oncology · 2016Review
- Update on medical treatment for Cushing's disease.Clinical diabetes and endocrinology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing's disease (CD) is caused by a corticotroph, adrenocorticotropic-hormone (ACTH)-secreting pituitary adenoma resulting in significant morbidity and mortality. Transsphenoidal surgery is the initial treatment of choice in almost all cases. Remission rates for microadenomas are good at 65-90 % (with an experienced neurosurgeon) but remission rates are much lower for macroadenomas. However, even after postoperative remission, recurrence rates are high and can be seen up to decades after an initial diagnosis. Repeat surgery or radiation can be useful in these cases, although both have clear limitations with respect to efficacy and/or side effects. Hence, there is a clear unmet need for an effective medical treatment. Currently, most drugs act by inhibiting steroidogenesis in the adrenal glands. Most is known about the effects of ketoconazole and metyrapone. While effective, access to ketoconazole and metyrapone is limited in many countries, experience with long-term use is limited, and side effects can be significant. Recent studies have suggested a role for a pituitary-directed therapy with new multireceptor ligand somatostatin analogs (e.g., pasireotide, recently approved in Europe for treatment of CD), second-generation dopamine agonists, or a combination of both. Mifepristone (a glucocorticoid receptor antagonist) is another promising drug, recently approved by the FDA for treatment of hyperglycemia associated with Cushing's syndrome. We review available medical treatments for CD with a focus on the two most recent compounds referenced above. Our aim is to expand awareness of current research, and the possibilities afforded by available medical treatments for this mesmerizing, but often frightful disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.